Raymond James raised the firm’s price target on Zimmer Biomet (ZBH) to $113 from $104 and keeps an Outperform rating on the shares. Zimmer Biomet reported “decent” Q2 results and an “encouraging” tone for the second half, the analyst tells investors in a research note. Growth is poised to accelerate in the second half, with growth supported by various new product launches that help the narrative, the firm adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target raised to $96 from $91 at UBS
- Zimmer Biomet Holdings: Balancing Strong Segment Growth with US Knee Challenges – Hold Rating Maintained
- Cautious Outlook and Hold Recommendation for Zimmer Biomet Holdings Amid Volatility Concerns
- Zimmer Biomet Reports Strong Q2 2025 Results
- Zimmer Biomet Holdings: Hold Rating Maintained Amid Stable Growth and Second-Half Optimism